英文字典中文字典Word104.com



中文字典辭典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z   







請輸入英文單字，中文詞皆可：

innards    音標拼音: ['ɪnɚdz]
n. 內臟

內臟

innards
n 1: internal organs collectively (especially those in the
abdominal cavity); "`viscera' is the plural form of
`viscus'" [synonym: {viscera}, {entrails}, {innards}]

innards \innards\ n.
The internal organs of an animal collectively especially
those in the abdominal cavity.

Syn: viscera.
[WordNet 1.5]

請選擇你想看的字典辭典：
單詞字典翻譯
innards查看　innards　在Google字典中的解釋Google英翻中〔查看〕
innards查看　innards　在Yahoo字典中的解釋Yahoo英翻中〔查看〕

安裝中文字典英文字典查詢工具!


中文字典英文字典工具:
選擇顏色:
輸入中英文單字

































































英文字典中文字典相關資料:
  • BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U. S. FDA . . .
    BEQALZI™ (sonrotoclax) is a BCL-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory (R R) mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor
  • FDA Approves Next-Gen Agent for Mantle Cell Lymphoma - Medscape
    The FDA has granted accelerated approval to sonrotoclax (Beqalzi, BeOne Medicines), for the treatment of certain adults with relapsed or refractory mantle cell lymphoma (MCL) Specifically, the
  • FDA Approves Beqalzi for Relapsed Mantle Cell Lymphoma
    FDA grants accelerated approval to Beqalzi (sonrotoclax) for relapsed or refractory mantle cell lymphoma in adults after prior therapies The U S Food and Drug Administration (FDA) has granted accelerated approval to Beqalzi (sonrotoclax) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL)
  • FDA Approves Sonrotoclax for Mantle Cell Lymphoma . . .
    Treatment Advances On May 13, 2026, the U S Food and Drug Administration (FDA) approved sonrotoclax (Beqalzi, BeOne Medicines) for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two prior treatments, including a BTK inhibitor MCL is a rare and often aggressive type of non-Hodgkin lymphoma
  • Sonrotoclax Approval Delivers a Long-Awaited New Option for . . .
    The FDA approved sonrotoclax (Beqalzi; BeOne Medicines) for the treatment of adult patients with relapsed or refractory (R R) mantle cell lymphoma (MCL), after at least 2 lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor The decision makes sonrotoclax the first B-cell lymphoma 2 (BCL2) inhibitor indicated for R R MCL 1 What is Sonrotoclax?
  • Sonrotoclax Granted Accelerated Approval for R R Mantle Cell . . .
    Today’s approval of Beqalzi represents critical progress for patients with mantle cell lymphoma and reinforces our strategy of building foundational medicines designed to raise the standard of
  • FDA Approves Sonrotoclax for Relapsed Refractory Mantle Cell . . .
    The FDA has granted accelerated approval to sonrotoclax (Beqalzi) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least 2 lines of systemic
  • FDA Grants Accelerated Approval to Beqalzi for R R Mantle . . .
    The FDA granted accelerated approval to sonrotoclax for adults with relapsed or refractory mantle cell lymphoma after prior systemic therapies
  • FDA Grants Accelerated Approval to Beqalzi - Drugs. com
    Beqalzi™ (sonrotoclax) is a BCL-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory (R R) mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor
  • The U. S. Food and Drug Administration (FDA) Approves . . .
    Update on Mantle Cell Lymphoma Webinar Led by a lymphoma expert, this virtual interactive program will provide an overview of mantle cell lymphoma (MCL), including the latest treatment approaches, emerging research, and the role of clinical trials Attendees will also have the opportunity to ask questions during a live Q A session





中文字典-英文字典  2005-2009

|中文姓名英譯,姓名翻譯 |简体中文英文字典